Related Experiment Video

Updated: Mar 18, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease

Natale Vazzana1, Francesca Santilli1, Stefano Lattanzio1

  • 1Internal Medicine and Center of Excellence on Aging, "G. d'Annunzio" University Foundation, Chieti, Italy.

European Journal of Internal Medicine
|July 9, 2016
PubMed

Insights

Platelet activation and oxidative stress increase with chronic kidney disease (CKD) progression. Anemia in CKD is linked to this platelet activation, potentially increasing cardiovascular risk.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Accelerated atherothrombosis is a complication in chronic kidney disease (CKD).
  • Mechanisms underlying this complication are not fully understood.
  • Thromboxane (TX)-dependent platelet activation and its determinants in CKD require further investigation.

Purpose of the Study:

  • To assess thromboxane (TX)-dependent platelet activation in CKD patients.
  • To identify factors influencing TX biosynthesis in CKD, including oxidative stress, inflammation, and anemia.
  • To explore the relationship between kidney function, anemia, and platelet activation.

Main Methods:

  • Cross-sectional study comparing urinary 8-iso-PGF2α (oxidative stress marker) and 11-dehydro-TXB2 (platelet activation marker).
  • Included 115 patients with stage 1-4 CKD.
  • Multivariate analysis to identify independent predictors of TX biosynthesis.

Main Results:

  • Urinary 11-dehydro-TXB2 and 8-iso-PGF2α levels increased with CKD stage.
  • Both markers were inversely associated with estimated glomerular filtration rate (eGFR) and hemoglobin levels.
  • Urinary 8-iso-PGF2α, hemoglobin, and eGFR were independent predictors of urinary 11-dehydro-TXB2.

Conclusions:

  • Patients with CKD exhibit persistent platelet activation, even in early stages.
  • This activation is linked to kidney function and oxidative stress.
  • Anemia in CKD is independently associated with TX-dependent platelet activation, suggesting a link to cardiovascular risk.
Abstract

Keywords:
11-dehydro-TXB(2)8-iso-PGF(2α)CKDProstanoidseGFR

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.3K
Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.6K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
890
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
545
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
296
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
566
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
315